Literature DB >> 20379446

Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma.

Shin Wha Lee1, Yong-Man Kim, Ha-Young Lee, Dae-Yeon Kim, Jong-Hyeok Kim, Joo-Hyun Nam, Young-Tak Kim.   

Abstract

OBJECTIVE: Regulatory T lymphocytes evoke the immune tolerance by suppressing and inactivating cytotoxic T lymphocytes. The objective of this study was to compare the proportion of regulatory T lymphocytes, precisely defined as CD4(+)CD25(high+)Foxp3(+) T lymphocytes, in primary and recurrent ovarian carcinoma before and after ex vivo expansion of ascites with interleukin-2 (IL-2).
METHODS: Ascitic fluid samples were obtained from 26 patients with ovarian carcinoma. Lymphocytes were isolated from ascites and cell markers were analyzed by flow cytometry using anti-CD3/CD4/CD8/CD16/CD56/CD25 and anti-Foxp3 antibodies. Lymphocytes were incubated for 2 to 3 weeks and expanded ex vivo by IL-2 stimulation and their phenotypes were analyzed by flow cytometry.
RESULTS: Following ex vivo expansion, ascitic fluid lymphocytes increased by a greater extent in the recurrent group than in the primary group. The proportion of ex vivo-expanded lymphocytes changed as follows; CD4(+) T lymphocytes increased, CD8(+) T lymphocytes decreased, and the proportion of CD3(-)CD16(+)56(+) NK cells was unchanged. The proportion of CD4(+)CD25(high+)Foxp3(+) regulatory T lymphocytes in CD4(+) T lymphocytes increased after ex vivo expansion in both groups, but to a greater degree in the recurrent group.
CONCLUSION: This study showed that regulatory T lymphocytes, neither cytotoxic T lymphocytes nor NK cells, were extensively increased after ex vivo expansion, especially in recurrent ovarian carcinoma. These results may provide information that helps to guide the future development of adoptive immunotherapy against ovarian carcinoma.

Entities:  

Keywords:  Ascites; Ex vivo expansion; Foxp3; Ovarian carcinoma; Regulatory T lymphocyte

Year:  2010        PMID: 20379446      PMCID: PMC2849947          DOI: 10.3802/jgo.2010.21.1.38

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  27 in total

Review 1.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

Authors:  Jason D Fontenot; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

Review 2.  Immunotherapy and gene therapy of cancer.

Authors:  S A Rosenberg
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

3.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 4.  Tumor-induced immune dysfunction: the macrophage connection.

Authors:  K D Elgert; D G Alleva; D W Mullins
Journal:  J Leukoc Biol       Date:  1998-09       Impact factor: 4.962

Review 5.  Immunology and immunotherapy of human cancer: present concepts and clinical developments.

Authors:  A J Bremers; G Parmiani
Journal:  Crit Rev Oncol Hematol       Date:  2000-04       Impact factor: 6.312

6.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.

Authors:  A F Ochsenbein; S Sierro; B Odermatt; M Pericin; U Karrer; J Hermans; S Hemmi; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

7.  Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.

Authors:  R S Freedman; B Tomasovic; S Templin; E N Atkinson; A Kudelka; C L Edwards; C D Platsoucas
Journal:  J Immunol Methods       Date:  1994-01-03       Impact factor: 2.303

8.  Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.

Authors:  K Kono; F Salazar-Onfray; M Petersson; J Hansson; G Masucci; K Wasserman; T Nakazawa; P Anderson; R Kiessling
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

9.  Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.

Authors:  H Jonuleit; E Schmitt; M Stassen; A Tuettenberg; J Knop; A H Enk
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  2 in total

1.  Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma.

Authors:  Yong Wook Jung; Seok Ju Seong; Chong Taik Park
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

2.  15-PGDH Expression in Gastric Cancer: A Potential Role in Anti-Tumor Immunity.

Authors:  Yaling Li; Junjie Li; Juanjuan Dong; Lei Zhang; Dongling Liu; Jianzheng He; Yali She; Chengxu Ma; Yongqi Liu
Journal:  Cancer Manag Res       Date:  2020-08-19       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.